HOOK News and Press, HOOKIPA Pharma Inc. From 01/18/22

First patient dosed with HB-200 and pembrolizumab combination for treatment of 1 st -line advanced/metastatic head and neck cancer in Phase 2 arm of ongoing Phase 1/2 trial Fast Track Designation granted for HB-200 in combination with pembrolizumab for treatment of 1 st -l...

NEW YORK and VIENNA, Austria, Jan. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company will present at the virtual H.C....

NEW YORK and VIENNA, Austria, Dec. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will partic...

NEW YORK and VIENNA, Austria, Nov. 12, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will partic...

HOOKIPA Pharma (NASDAQ:HOOK): Q3 GAAP EPS of -$0.61 misses by $0.05. Revenue of $3.87M (-4.2% Y/Y) misses by $1.85M. Press Release For further details see: HOOKIPA Pharma EPS misses by $0.05, misses on revenue

Clinical collaboration with Merck & Co., Inc., Kenilworth, NJ, USA, set to evaluate HB-201 in combination with pembrolizumab in 1 st - and 2 nd -line HNSCC patients Based on recent strong data updates, HOOKIPA advancing HB-201 to Phase 2, prioritizing immuno...

Based on positive interim Phase 1 data, HOOKIPA initiates Phase 2 study to assess HB-201 in combination with pembrolizumab in 1 s t and 2 nd line head and neck cancer Interim Phase 1 HB-200 data continue to show high levels of tumor-specific CD8+ T cells, promising ear...

NEW YORK and VIENNA, Austria, Nov. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release third quarter 2021 financial...

Comprehensive review highlights potential of HOOKIPA’s versatile arenavirus platform as a new immunotherapy strategy to address critical unmet needs in cancer Pre-clinical and clinical data showcase potent, tumor-specific CD8+ T cell responses following intravenous administ...

Clinical collaboration to assess HB-200 in combination with KEYTRUDA ® (pembrolizumab) as first-line treatment HOOKIPA poised to advance clinical development program with randomized Phase 2 study in 2022 NEW YORK and VIENNA, Austria, Sept. 15...